[go: up one dir, main page]

BRPI0607975A2 - forma farmacêutica contendo oxicodona e naloxona - Google Patents

forma farmacêutica contendo oxicodona e naloxona

Info

Publication number
BRPI0607975A2
BRPI0607975A2 BRPI0607975-0A BRPI0607975A BRPI0607975A2 BR PI0607975 A2 BRPI0607975 A2 BR PI0607975A2 BR PI0607975 A BRPI0607975 A BR PI0607975A BR PI0607975 A2 BRPI0607975 A2 BR PI0607975A2
Authority
BR
Brazil
Prior art keywords
naloxone
dosage form
sub
form containing
containing oxycodone
Prior art date
Application number
BRPI0607975-0A
Other languages
English (en)
Inventor
Petra Leyendecker
Michael Hopp
Kevin Smith
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34933990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607975(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0607975A2 publication Critical patent/BRPI0607975A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMA FARMACêUTICA CONTENDO OXICODONA E NALOXONA. A presente invenção se refere a uma forma farmacêutica que compreende oxicodona e naloxona e que é caracterizada por parâmetros específicos in vivo como t~ max~, C~ max~, valor AUCt, classificação da função intestinal média e/ou a duração da eficácia analgésica.
BRPI0607975-0A 2005-02-28 2006-02-28 forma farmacêutica contendo oxicodona e naloxona BRPI0607975A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05004377A EP1695700A1 (en) 2005-02-28 2005-02-28 Dosage form containing oxycodone and naloxone
PCT/EP2006/060341 WO2006089973A2 (en) 2005-02-28 2006-02-28 Dosage form containing oxycodone and naloxone

Publications (1)

Publication Number Publication Date
BRPI0607975A2 true BRPI0607975A2 (pt) 2009-10-27

Family

ID=34933990

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607975-0A BRPI0607975A2 (pt) 2005-02-28 2006-02-28 forma farmacêutica contendo oxicodona e naloxona

Country Status (26)

Country Link
US (5) US20080145429A1 (pt)
EP (5) EP1695700A1 (pt)
JP (2) JP2008531650A (pt)
KR (1) KR20070107805A (pt)
CN (2) CN101128191A (pt)
AT (1) ATE517611T1 (pt)
AU (2) AU2006217870B2 (pt)
BR (1) BRPI0607975A2 (pt)
CA (3) CA2599156C (pt)
CY (1) CY1111967T1 (pt)
DE (2) DE19167974T1 (pt)
DK (2) DK1855657T3 (pt)
ES (1) ES2370409T3 (pt)
FI (1) FI7750U1 (pt)
HR (1) HRP20110775T1 (pt)
IL (2) IL185514A0 (pt)
ME (1) ME01262B (pt)
MX (1) MX2007010494A (pt)
NZ (1) NZ588875A (pt)
PL (1) PL1855657T3 (pt)
PT (1) PT1855657E (pt)
RS (1) RS51984B (pt)
RU (1) RU2428985C2 (pt)
SI (1) SI1855657T1 (pt)
UA (1) UA93543C2 (pt)
WO (1) WO2006089973A2 (pt)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1436012B1 (en) 2001-10-18 2017-12-20 Nektar Therapeutics Polymer conjugates of opioid antagonists
KR100784341B1 (ko) 2002-04-05 2007-12-13 유로-셀띠끄 소시에떼 아노님 활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
EA201100544A1 (ru) * 2006-11-07 2012-01-30 Нектар Терапьютикс Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
US20090004231A1 (en) 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
EP2042176A1 (en) * 2007-09-26 2009-04-01 Euro-Celtique S.A. Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease
KR20100121463A (ko) 2007-12-17 2010-11-17 라보팜 인코포레이트 오용 예방적 방출 제어형 제제
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
HRP20161307T1 (hr) 2008-05-09 2016-12-02 Grünenthal GmbH Postupak za pripravu praškaste formulacije međuproizvoda i konačni kruti oblik doziranja uz korištenje koraka zgrušavanja raspršivanjem
KR20110026013A (ko) * 2008-07-07 2011-03-14 유로-셀티큐 에스.에이. 요폐의 치료를 위한 아편유사제 길항제의 용도
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
SMT201900023T1 (it) * 2009-03-10 2019-02-28 Euro Celtique Sa Composizioni farmaceutiche a rilascio immediato comprendenti ossicodone e naloxone
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CN102821757B (zh) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
NZ603173A (en) 2010-05-10 2014-10-31 Euro Celtique Sa Manufacturing of active-free granules and tablets comprising the same
KR20130030260A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 히드로모르폰 및 날록손을 포함하는 제약 조성물
BR112013003150B1 (pt) * 2010-08-13 2022-01-18 Euro-Celtique S.A. Uso de hidroxipropil celulose para a fabricação de formulações estáveis em armazenagem
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
NZ612837A (en) * 2010-12-28 2014-11-28 Euro Celtique Sa A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson’s disease
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
WO2013156850A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
DE112014005175T5 (de) 2013-11-13 2016-07-21 Euro-Celtique S.A. Hydromorphon und Naloxon für die Behandlung von Schmerzen und Opioid-Darm-Dysfunktions-Syndrom
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
HK1231370A1 (zh) 2014-03-14 2017-12-22 欧皮安特制药有限公司 鼻用药物产品及其使用方法
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016016431A1 (en) * 2014-08-01 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160256451A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Dosage of naloxone
US20160256453A1 (en) * 2015-03-06 2016-09-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
WO2016193456A2 (en) * 2015-06-03 2016-12-08 Develco Pharma Schweiz Ag Opioid receptor antagonist for use in treating patients with severe constipation
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US12201629B2 (en) 2017-06-30 2025-01-21 Purdue Pharma L.P. Method of treatment and dosage forms thereof
US12475984B2 (en) * 2019-08-05 2025-11-18 Rxassurance Corporation Techniques for providing interactive clinical decision support for drug dosage reduction
US20240131022A1 (en) * 2022-03-11 2024-04-25 John Abernethy Opioid overdose reversal mixtures

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (pt) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (pt) * 1967-11-02 1969-05-06
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
FR2183546B1 (pt) * 1972-05-10 1975-06-20 Servier Lab
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3916889A (en) * 1973-09-28 1975-11-04 Sandoz Ag Patient ventilator apparatus
US3966940A (en) 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966040A (en) * 1975-03-05 1976-06-29 Hazelwood John E Combined vibratory feeder drive unit, vibratory feeder bowl, and parts separator
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4457933A (en) 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4668685A (en) * 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5273760A (en) * 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4325465B4 (de) * 1993-07-29 2004-03-04 Zenz, Michael, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5866154A (en) * 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5865161A (en) * 1995-01-04 1999-02-02 Bruce; Norman R. Baseball pitching device
US20020006964A1 (en) * 1995-05-16 2002-01-17 Young James W. Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6207142B1 (en) * 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
DK1009387T3 (da) * 1997-07-02 2006-08-14 Euro Celtique Sa Stabiliserede tramadolformuleringer med langvarig frigivelse
NZ505192A (en) * 1997-12-22 2003-05-30 Euro Celtique S A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
KR100597517B1 (ko) * 1998-03-27 2006-07-10 파마시아 앤드 업존 캄파니 엘엘씨 카베르골린의 하지 불안 증후군 치료 용도
US20030178031A1 (en) * 1999-05-07 2003-09-25 Du Pen, Inc. Method for cancer pain treatment
EP1192789B1 (en) * 1999-06-11 2008-10-15 Telstra Corporation Limited A method of developing an interactive system
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
US6258042B1 (en) 1999-09-17 2001-07-10 James S. Factor Visual analog scale and method of use for the diagnosis and/or treatment of physical pain
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
ES2540103T3 (es) * 2000-02-08 2015-07-08 Euro-Celtique S.A. Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
WO2002085839A1 (en) * 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2002092059A1 (en) * 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
CA2446550C (en) * 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DK1416842T3 (da) * 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
BR0212019A (pt) * 2001-08-06 2005-08-09 Euro Celtique Sa Formas de dosagem, métodos para o tratamento da dor, métodos de preparação de uma forma de dosagem e métodos para impedir o abuso de uma forma de dosagem
PL367427A1 (en) * 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
MXPA04002709A (es) * 2001-09-24 2005-06-06 Johnson & Johnson Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.
DK1482835T3 (da) 2002-03-06 2013-01-07 Euro Celtique Sa Analog skala til måling af smerte
KR100784341B1 (ko) * 2002-04-05 2007-12-13 유로-셀띠끄 소시에떼 아노님 활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
CA2491572C (en) * 2002-07-05 2010-03-23 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone

Also Published As

Publication number Publication date
US20140031382A1 (en) 2014-01-30
DK200700248U1 (da) 2007-12-14
EP1855657B1 (en) 2011-07-27
DE19167974T1 (de) 2021-12-30
CA2599156A1 (en) 2006-08-31
AU2006217870B2 (en) 2008-12-18
NZ588875A (en) 2012-02-24
AU2009201019B2 (en) 2011-05-26
EP2258353A3 (en) 2012-05-09
ME01262B (me) 2013-06-20
KR20070107805A (ko) 2007-11-07
RU2428985C2 (ru) 2011-09-20
IL196539A0 (en) 2011-07-31
HRP20110775T1 (hr) 2011-11-30
ATE517611T1 (de) 2011-08-15
JP6235962B2 (ja) 2017-11-22
EP1695700A1 (en) 2006-08-30
CA2599156C (en) 2012-05-01
WO2006089973A2 (en) 2006-08-31
EP3578173A1 (en) 2019-12-11
AU2006217870A1 (en) 2006-08-31
CA2960011A1 (en) 2006-08-31
CN101128191A (zh) 2008-02-20
WO2006089973A3 (en) 2006-12-28
EP3578173B1 (en) 2022-10-26
HK1111604A1 (en) 2008-08-15
EP2258353A2 (en) 2010-12-08
EP2962686B1 (en) 2019-04-10
EP2962686A1 (en) 2016-01-06
DK1855657T3 (da) 2011-10-17
US20120225901A1 (en) 2012-09-06
US20110172259A1 (en) 2011-07-14
EP1855657A2 (en) 2007-11-21
US20080145429A1 (en) 2008-06-19
DK200700248U3 (da) 2008-02-08
RS51984B (sr) 2012-02-29
JP2014169303A (ja) 2014-09-18
MX2007010494A (es) 2008-01-16
DE202006020095U1 (de) 2007-11-08
CA2768075A1 (en) 2006-08-31
PL1855657T3 (pl) 2012-03-30
US20180008593A1 (en) 2018-01-11
IL185514A0 (en) 2008-01-06
UA93543C2 (ru) 2011-02-25
FIU20070153U0 (fi) 2007-04-13
ES2370409T3 (es) 2011-12-15
CY1111967T1 (el) 2015-11-04
JP2008531650A (ja) 2008-08-14
CN104027297A (zh) 2014-09-10
AU2009201019A1 (en) 2009-04-02
RU2007135991A (ru) 2009-04-10
SI1855657T1 (sl) 2011-11-30
FI7750U1 (fi) 2008-01-22
PT1855657E (pt) 2011-10-31

Similar Documents

Publication Publication Date Title
BRPI0607975A2 (pt) forma farmacêutica contendo oxicodona e naloxona
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
ZA200704130B (en) Protassium salt of an HIV integrase inhibitor
LU92864I2 (fr) Cobicistat ou un de ses sels pharmaceutiquement acceptables
WO2009156462A3 (en) Organic compounds
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
NL1029015A1 (nl) Therapeutische verbindingen.
CY2014012I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
NL1028192A1 (nl) Gesubstitueerde chinolineverbindingen.
EP2042484A4 (en) CARGO TRANSPORT-PAINT
NO20064555L (no) HIV-integraseinhibitorer.
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
EP1862070A3 (en) Microbicidal composition
WO2007130507A3 (en) Acute pain medications based on fast acting diclofenac-opioid combinations
FR2899254B1 (fr) Tete de douchette avec dosage de savons, sels et similaires.
WO2007115287A3 (en) Combination of organic compounds
FR2855813B1 (fr) Distributeur de gobelets.
GB2421245B (en) Low Dosage Naphthenate Inhibitors
DE602005020787D1 (de) Chemische verbindungen i
WO2009095583A3 (fr) Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale
GB0605715D0 (en) Treatment of laminitis
IS7970A (is) PDE4-hemlar til að meðhöndla eitlafrumuæxli
WO2007092741A3 (en) Hydroxylamines and derivatives as anti-angiogenic agents

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: EURO-CELTIQUE S.A (LU)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL